[1]陈京京,陈盈玲,单浩杰,等.T2DM患者连续血糖监测血糖风险指数与骨代谢标志物、骨密度相关性分析[J].陕西医学杂志,2025,54(6):765-768,774.[doi:DOI:10.3969/j.issn.1000-7377.2025.06.008]
　CHEN Jingjing,CHEN Yingling,SHAN Haojie,et al.Correlation between GRI and Bone metabolism,BMD in T2DM patients[J].,2025,54(6):765-768,774.[doi:DOI:10.3969/j.issn.1000-7377.2025.06.008]
点击复制

T2DM患者连续血糖监测血糖风险指数与骨代谢标志物、骨密度相关性分析

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
54
期数:
2025年6期
页码:
765-768,774
栏目:
临床研究
出版日期:
2025-06-05

文章信息/Info

Title:
Correlation between GRI and Bone metabolism,BMD in T2DM patients
作者:
陈京京1; 2; 陈盈玲1; 2; 单浩杰2; 蒋伏松1; 2; 于晓巍2
（1.江西中医药大学，江西 南昌 330004；2.上海交通大学医学院附属第六人民医院，上海 200233）
Author(s):
CHEN Jingjing1; 2; CHEN Yingling1; 2; SHAN Haojie2; JIANG Fusong1; 2; YU Xiaowei2
(1.Jiangxi University of Chinese Medicine,Nanchang 330004,China;2.Sixth People’s Hospital，School of Medicine,Shanghai Jiao Tong University，Shanghai 200233，China)
关键词:
2型糖尿病; 骨代谢; 骨密度; 骨质疏松; 连续血糖监测; 血糖风险指数
Keywords:
Type 2 diabetes mellitus; Bone metabolism; Bone mineral density; Osteoporosis; Continuous glucose monitoring; Glycemic Risk Index
分类号:
R 587.1
DOI:
DOI:10.3969/j.issn.1000-7377.2025.06.008
文献标志码:
A
摘要:
目的：分析2型糖尿病(T2DM)患者连续血糖监测(CGM)血糖风险指数(GRI)与骨代谢、骨密度（BMD）的相关性。方法：选取T2DM住院患者474例为研究对象，均接受72 h连续血糖监测，并计算GRI。检测血清骨代谢标志物骨钙素N端中分子片段（N-MID OC）、Ⅰ型前胶原氨基端前肽（PINP）、甲状旁腺激素（PTH）、β胶原降解产物（β-CTX）、25-羟基维生素D3[25(OH)VD3]、降钙素（CT）及BMD。比较不同骨量患者一般资料、GRI、骨代谢标志物及BMD，并采用Spearman相关性分析和多元线性回归分析GRI与骨代谢标志物、腰椎BMD、髋部BMD的相关性。结果：根据BMD结果将患者分为骨量正常组（199例）、骨量减少组（179例）和骨质疏松组（96例）。骨量正常组年龄、女性占比人数、高密度脂蛋白低于骨量减少组和骨质疏松组，BMI高于骨量减少组和骨质疏松组（均P<0.05）。骨量正常组甘油三酯和2 h餐后血糖高于骨质疏松组（均P<0.05）。三组N-MID OC、PINP、β-CTX和CT比较差异有统计学意义（均P<0.05）。Spearman相关性分析显示，GRI与N-MID OC、PINP、25(OH)VD3及髋部BMD呈负相关(均P<0.05)。多元线性回归分析显示，GRI与N-MID OC、25(OH)VD3、髋部BMD呈负相关(均P<0.05)。结论：T2DM患者GRI与骨代谢标志物N-MID OC、25(OH)VD3和髋部BMD呈负相关。
Abstract:
Objective:To analyze the correlation between continuous glucose monitoring (CGM) Glycemic Risk Index (GRI) and bone metabolism,bone mineral density (BMD) in patients with type 2 diabetes mellitus (T2DM).Methods：A total of 474 hospitalized patients with T2DM were selected as study subjects,all of whom received 72-hour continuous glucose monitoring,and GRI was calculated.Serum bone metabolism markers including N-terminal mid-fragment of osteocalcin (N-MID OC),propeptide of type Ⅰ procollage (PINP),parathyroid hormone (PTH),β-collagen degradation products (β-CTX),25-hydroxyvitamin D3 [25(OH)VD3],calcitonin (CT) and BMD were detected.The general data,GRI,bone metabolism indexes and BMD of patients with different bone mass were compared.Spearman correlation analysis and multiple linear regression analysis were used to analyze the correlation between GRI and bone metabolism markers,lumbar BMD,and hip BMD.Results:According to the results of BMD,the patients were divided into normal bone mass group (199 cases),osteopenia group (179 cases),and osteoporosis group (96 cases).In the group with normal bone mass,age,proportion of females,and high-density lipoprotein level were lower than those in the osteopenia group and the osteoporosis group,and BMI was higher than that in the osteopenia group and the osteoporosis group (all P<0.05).Triglyceride level and 2-hour postprandial blood glucose in the normal bone mass group were higher than those in the osteoporosis group (all P<0.05).Statistically significant differences were observed among three groups for N-MID OC,PINP,β-CTX and CT.Spearman correlation analysis showed that GRI was negatively correlated with N-MID OC,PINP,25(OH)VD3 and hip BMD (all P<0.05).Multiple linear regression analysis showed that GRI was negatively correlated with N-MID OC,25(OH)VD3 and hip BMD (all P<0.05).Conclusion:GRI was negatively correlated with bone metabolism indexes N-MID OC,25(OH)VD3 and hip BMD in T2DM patients.

参考文献/References:

[1]EBELING P R,NGUYEN H H,ALEKSOVA J,et al.Secondary osteoporosis[J].Endocr Rev,2022,43(2)：240-313.
[2]MERLOTTI D,GENNARI L,DOTTA F,et al.Mechanisms of impaired bone strength in type 1 and 2 diabetes[J].Nutr Metab Cardiovasc Dis,2010,20(9)：683-690.
[3]SACKS D B,ARNOLD M,BAKRIS G L,et al.Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus[J].Diabetes Care,2023,46(10)：e151-e199.
[4]LIU X,CHEN F,LIU L,et al.Prevalence of osteoporosis in patients with diabetes mellitus：A systematic review and meta-analysis of observational studies[J].BMC Endocr Disord,2023,23(1)：1.
[5]KLONOFF D C,WANG J,RODBARD D,et al.A glycemia risk index (GRI) of hypoglycemia and hyperglycemia for continuous glucose monitoring validated by clinician ratings[J].J Diabetes Sci Technol,2023,17(5)：1226-1242.
[6]BAUER D,KREGE J,LANE N,et al.National bone health alliance bone turnover marker project：Current practices and the need for us harmonization,standardization,and common reference ranges[J].Osteoporos Int,2012,23(10)：2425-2433.
[7]中华医学会糖尿病分会.中国2型糖尿病防治指南（2020年版）（上）[J].中国实用内科杂志,2021,41(8)：668-695.
[8]RICKHAM P P.Human experimentation.Code of ethics of the world medical association.Declaration of helsinki[J].Br Med J,1964,2(5402)：177.
[9]中华医学会骨质疏松和骨矿盐疾病分会.原发性骨质疏松症诊疗指南(2022)[J].中华骨质疏松和骨矿盐疾病杂志,2022,15(6)：573-611.
[10]ARAUJO I M D,MOREIRA M L M,PAULA F J A D.Diabetes and bone[J].Arch Endocrinol Metab,2022,66：633-641.
[11]史凡凡,赵继荣,马同,等.中医药治疗糖尿病性骨质疏松症从“脾肾论治”机制[J].陕西中医,2022,43(5)：604-607.
[12]OEI L,RIVADENEIRA F,ZILLIKENS M C,et al.Diabetes,diabetic complications,and fracture risk[J].Curr Osteoporos Rep,2015,13(2)：106-115.
[13]HUANG R,WANG H,SHEN Z,et al.Increased glycemic variability evaluated by continuous glucose monitoring is associated with osteoporosis in type 2 diabetic patients[J].Front Endocrinol (Lausanne),2022,13：861131.
[14]贾真,何旺,张渭涛,等.2型糖尿病患者骨转换指标与血糖的相关性[J].陕西医学杂志,2017,46(8)：1083-1084.
[15]郭向东,马波.2型糖尿病患者血清胰岛素水平与骨代谢关联研究[J].陕西医学杂志,2019,48(1)：77-79.
[16]BATTELINO T,DANNE T,BERGENSTAL R M,et al.Clinical targets for continuous glucose monitoring data interpretation：Recommendations from the international consensus on time in range[J].Diabetes Care,2019,42(8)：1593-1603.
[17]贾伟平.血糖监测技术的进步与展望[J].上海交通大学学报(医学版),2022,42(9)：1171-1175.
[18]WANG Y,LU J,NI J,et al.Association between glycaemia risk index (GRI) and diabetic retinopathy in type 2 diabetes：A cohort study[J].Diabetes Obes Metab,2023,25：2457-2463.
[19]TANG Y,ZHANG P,LI L,et al.Diabetic peripheral neuropathy and glycemia risk index in type 2 diabetes：A cross-sectional study[J].Diabetes Metab Syndr Obes,2024,17：4191-4198.
[20]YOO J H,KIM J Y,KIM J H.Association between continuous glucose monitoring-derived glycemia risk index and albuminuria in type 2 diabetes[J].Diabetes Technol Ther,2023,25：726-735.
[21]CAI L,SHEN W,LI J,et al.Association between glycemia risk index and arterial stiffness in type 2 diabetes[J].J Diabetes Investig,2024,15(5)：614-622.
[22]CIPRIANI C,COLANGELO L,SANTORI R,et al.The interplay between bone and glucose metabolism[J].Front Endocrinol,2020,11：122.
[23]曹永红,章容,叶军,等.血糖波动对绝经后女性2型糖尿病患者骨密度的影响[J].中国老年学杂志,2022,42(11)：2638-2641.
[24]陈逸青,陈福华,应瑞雪,等.老年男性2型糖尿病患者血糖波动与骨代谢指标及骨密度的相关性研究[J].标记免疫分析与临床,2024,31(8)：1487-1494.
[25]YANG J,ZHENG C,WANG Y,et al.Correlation between mean amplitude of glycemic excursion and bone turnover markers in patients with type 2 diabetes：A cross-sectional study[J].Diabetes Meta Syndr Obesity,2023,10(16)：397-407.

相似文献/References:

[1]李艳艳,贾 伟△.24h动态心电图在2型糖尿病合并冠心病患者心律诊断中的价值分析[J].陕西医学杂志,2019,(1):61.
[2]刘毅龙,陈鹏宇,雷 江,等.SGLT2抑制剂在2型糖尿病合并心血管疾病治疗中的应用研究进展[J].陕西医学杂志,2019,(3):407.
[3]姚爱红.利拉鲁肽治疗2型糖尿病效果及对患者血脂、颈动脉内膜中层厚度的影响[J].陕西医学杂志,2019,(4):518.
　YAO Aihong..Effect of liraglutide on type 2 diabetes mellitus in patients with blood lipids and carotid intimamedia thickness[J].,2019,(6):518.
[4]李忆琴,吴礼凤,余晓君,等.中年2型糖尿病患者病程和HbA1c水平与认知功能相关性研究*[J].陕西医学杂志,2019,(6):722.
[5]徐 琳,贾睿博△,宋民喜,等.颗粒蛋白前体与糖尿病肾病关系探讨*[J].陕西医学杂志,2019,(8):1024.
[6]王荣锋,郁 昊,蒋新建.老年糖尿病患者血清25羟维生素D水平与骨质疏松相关性研究[J].陕西医学杂志,2019,(8):1032.
　WANG Rongfeng,YU Hao,JIANG Xinjian..The relationship between serum 25 hydroxy vitamin D and osteoporosis in elderly diabetic patients[J].,2019,(6):1032.
[7]王 荣,贾爱华,刘新艳 ,等.IGF1及其相关性因素对2型糖尿病并发骨质疏松的影响研究[J].陕西医学杂志,2019,(9):1163.
　WANG Rong,JIA Aihua,LIU Xinyan,et al.The effect of IGF1 and its related factors in type 2 diabetes complicated with osteoporosis[J].,2019,(6):1163.
[8]贾睿博,徐 琳△.2型糖尿病患者下肢血管病变相关危险因素调查研究[J].陕西医学杂志,2019,(11):1567.
[9]郭建强,赵俊宏,张分队,等.2型糖尿病视网膜病变患者血清HbA1c、CysC检测及临床意义*[J].陕西医学杂志,2020,49(5):619.
　GUO Jianqiang,ZHAO Junhong,ZHANG Fendui,et al.Changes of serum HbA1c and CysC in patients with type 2 diabetic retinopathy and their clinical significance[J].,2020,49(6):619.
[10]陈伟国,朱萧玲,常 盼,等.2型糖尿病患者冠状动脉狭窄程度危险因素分析*[J].陕西医学杂志,2020,49(6):672.[doi:DOI:10.3969/j.issn.10007377.2020.06.008]
　CHEN Weiguo,ZHU Xiaoling,CHANG Pan,et al.Risk factors of coronary stenosis in patients with type 2 diabetes mellitus[J].,2020,49(6):672.[doi:DOI:10.3969/j.issn.10007377.2020.06.008]
[11]郭向东,马 波△.2型糖尿病患者血清胰岛素水平与骨代谢关联研究*[J].陕西医学杂志,2019,(1):77.
　GUO Xiangdong,MA Bo..Association between serum insulin level and bone metabolismin patients with type 2 diabetes mellitus[J].,2019,(6):77.

备注/Memo

备注/Memo:
国家自然科学基金资助项目（82372387）；上海交通大学医工交叉研究基金资助项目（YG2024ZD19）
更新日期/Last Update: 2025-06-04